In metastatic castration resistant prostate cancer (mCRPC), taxane sequencing after initial docetaxel benefit remains a common clinical dilemma, with limited comparative evidence to guide rechallenge verse switching therapy.
Key evidence
A real world cohort study published inn JAMA network open found that docetaxel rechallenge was associated with longer overall survival that cabazitaxel in patients with mCRPC who had no progressed on first line docetaxel. Median overall survival favored docetaxel rechallenge, with consistent trends across secondary endpoints.
Clinical or research implications
For carefully selected patients who previously responded to docetaxel rechallenge may be a reasonable and potentially superior option to immediate taxane switching. Prospective studies and predictive markers are needed to refine patient selection.
Which clinical or molecular features best identity mCRPC patients likely to benefit from docetaxel rechallenge?
MBH/PS